Type 2 diabetes Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Type 2 diabetes is a chronic
progressive metabolic disorder, usually irreversible, that leads to impaired
metabolism of carbohydrates, fats, and proteins because of a lack of, or
ineffective use of, the hormone insulin. Three core pathophysiological
processes combine to produce type 2 diabetes: insulin resistance, defective
insulin secretion, and excess hepatic glucose production. The resulting
hyperglycemia leads to excess insulin production, followed by a decline in the
function and mass of pancreatic beta cells, leading to diabetes. For most
diabetic and prediabetic patients, a high BMI (> 30) is the predetermining
etiological factor for developing type 2 diabetes. A close link exists between
the prevalence of insulin resistance and obesity. Vascular inflammation
resulting from hyperglycemia is a critical factor in the emergence of
complications in late-stage diabetes. Both macro- and microvasculature are
affected, leading to retinopathy, neuropathy, nephropathy, and cardiovascular
disease.
- The prevalence rate of Type 2 diabetes varies from 8.5% to
11.8% of the population in the USA. However, the treated population is
~78% of the prevalent population.
Thelansis’s “Type 2 diabetes Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Type
2 diabetes treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Type 2 diabetes across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Type 2 diabetes Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment